Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Elacestrant dihydrochloride

Catalog No.: 16122810
Cas No.: 1349723-93-8
Purity : ≧98.0%

Elacestrant dihydrochloride, also known as RAD1901, is an orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of RAD1901, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, RAD1901 is able to cross the blood-brain barrier (BBB). 

For research use only. We do not sell to patients.

Chemical Information

NameElacestrant dihydrochloride
Iupac Chemical Name(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride 
SynonymsRAD1901 ; RAD-1901 ; RAD 1901 ; RAD1901 HCl ; Elacestrant dihydrochloride 
Molecular FormulaC30H40Cl2N2O2 
Molecular Weight531.56 
CAS Number1349723-93-8
Related CAS722533-56-4 (free base)

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
Request Bulk Quote Download MSDS Tel : +86-27-65522453   Email : sales@sun-shinechem.com
FormulationOff-white Solid
StorageDry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
SolubilitySoluble in DMSO 
HandlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. 
HS Code
Coming soon.
Cell study
Animal study
Clinical study
Not available

Chemical Structure

16122810 - Elacestrant dihydrochloride | CAS 1349723-93-8

Quick inquiry